Media coverage about OptiNose (NASDAQ:OPTN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OptiNose earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.9259453212051 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- -$0.76 EPS Expected for OptiNose Inc (OPTN) This Quarter (americanbankingnews.com)
- OptiNose Inc (OPTN) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- OptiNose (OPTN) Scheduled to Post Earnings on Tuesday (americanbankingnews.com)
- Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018 (finance.yahoo.com)
- OptiNose (OPTN) Now Covered by Analysts at Cantor Fitzgerald (americanbankingnews.com)
OPTN has been the subject of a number of recent analyst reports. Zacks Investment Research raised OptiNose from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Wednesday, July 18th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $34.00 price target on shares of OptiNose in a report on Wednesday, July 18th. ValuEngine raised OptiNose from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Cantor Fitzgerald started coverage on OptiNose in a report on Tuesday, August 7th. They issued an “overweight” rating and a $30.00 target price for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $30.50.
OptiNose traded down $0.03, hitting $20.98, during trading on Friday, Marketbeat reports. The company had a trading volume of 128,924 shares, compared to its average volume of 208,255. The company has a quick ratio of 9.50, a current ratio of 9.66 and a debt-to-equity ratio of 0.57. OptiNose has a 1-year low of $15.01 and a 1-year high of $30.00. The stock has a market capitalization of $798.52 million and a PE ratio of -3.73.
OptiNose (NASDAQ:OPTN) last released its earnings results on Monday, May 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.07). The business had revenue of $0.87 million during the quarter. analysts expect that OptiNose will post -3.15 earnings per share for the current fiscal year.
In other news, Director Sriram Venkataraman sold 2,875,000 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $20.92, for a total transaction of $60,145,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert P. O’neil purchased 2,000 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were purchased at an average cost of $22.75 per share, for a total transaction of $45,500.00. The disclosure for this purchase can be found here. Insiders own 67.80% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More: How to Use the New Google Finance Tool
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.